Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | GI-102 |
Synonyms | |
Therapy Description |
GI-102 is an immunocytokine comprising a CD80-IgG4-IL2v3 fusion protein, which that potentially induces antitumor immune activity (Journal for ImmunoTherapy of Cancer 2023;11,729; Journal for ImmunoTherapy of Cancer 2023;11,1062). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GI-102 | GI102|GI 102 | GI-102 is an immunocytokine comprising a CD80-IgG4-IL2v3 fusion protein, which that potentially induces antitumor immune activity (Journal for ImmunoTherapy of Cancer 2023;11,729; Journal for ImmunoTherapy of Cancer 2023;11,1062). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05824975 | Phase Ib/II | GI-102 | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 in Patients With Advanced Solid Tumors | Recruiting | USA | 1 |